Trial Profile
A Multi-center, Randomized, Double-blind, Parallel-group, Active-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of LXI-15028 Comparing With Esomeprazole in the Treatment of Erosive Esophagitis in Chinese Patients for up to 8 Weeks
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Apr 2020
Price :
$35
*
At a glance
- Drugs Tegoprazan (Primary) ; Esomeprazole
- Indications Erosive oesophagitis
- Focus Therapeutic Use
- Sponsors Shandong Luoxin Pharmaceutical
- 14 Apr 2020 Status changed from recruiting to completed.
- 31 Oct 2018 Status changed from not yet recruiting to recruiting.
- 16 Aug 2018 New trial record